⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1448594 | 1.00 | — | — | |
| SCHEMBL14996082 | 1.00 | — | — | |
| SCHEMBL8574655 | 0.86 | — | — | |
| SCHEMBL790370 | 0.73 | — | — | |
| SCHEMBL30298296 | 0.73 | THRB (0.32) | — | |
| SCHEMBL470639 | 0.73 | — | — | |
| SCHEMBL470592 | 0.73 | — | — | |
| SCHEMBL873627 | 0.73 | — | — | |
| SCHEMBL4143279 | 0.69 | — | — | |
| SCHEMBL19628631 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731623-A1 | CARBOLINE COMPOUNDS AND USE THEREOF | PTC Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4608823-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | F. Hoffmann-La Roche AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4587443-A1 | MACROCYCLIC CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2025-07-23 | — | — | EP | disclosed |
| EP-4568959-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| EP-4568972-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025110227-A1 | PYRAZOLE COMPOUND AND HARMFUL ORGANISM CONTROL AGENT | 日産化学株式会社 | 2025-05-30 | — | — | WO | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2025054368-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025006078-A1 | CARBOLINE COMPOUNDS AND USE THEREOF | PTC THERAPEUTICS, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2011147951-A1 | CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS | PROSIDION LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-06 | — | — | US | disclosed |
| WO-2011044001-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011030139-A1 | 4- (PYRIMIDIN-2-YL) -PIPERAZINE AND 4- (PYRIMIDIN-2-YL) -PIPERIDINE DERIVATIVES AS GPR119 MODULATORS | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065706-A1 | Therapeutic Agents 812 | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
| US-7879862-B2 | Central nervous system disorders; psychological disorders; anxiolytic agents; irritable bowel syndrome; antidepressants | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2011-02-01 | — | — | US | disclosed |
| US-7879862-B2 | Central nervous system disorders; psychological disorders; anxiolytic agents; irritable bowel syndrome; antidepressants | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2011-02-01 | — | — | US | disclosed |
| WO-2009011872-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20080194589-A1 | Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194589-A1 | Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-08-14 | — | — | US | disclosed |